La Roche Posay Effaclar Duo Dual Action Treatment 40ml

SPECIFICALLY FORMULATED FOR:

Specifically formulated for oily, blemish-prone skin in adults and teenagers. A dual action daily gel moisturiser that reduces the appearance of blemishes and blackheads, controls shine and helps protect the skin from the causes of red and brown coloured marks that are often left by spots. Hydrates skin for 24 hours. This cosmetic moisturiser is also suitable for acne-prone skin.

Anti-blemish moisturiser that corrects and hydrates oily skin.

Visibly reduces blemishes, controls shine and helps to reduce the appearance of marks.

For clearer skin in 4 weeks

ACTIVE:

Niacinamide helps to visibly reduce the appearance of spots.

Lipo Hydroxy Acid & Salicylic Acid work to unclog blocked pores.

Zinc PCA controls sebum to mattify skin and control shine.

Procerad helps to reduce the appearance of coloured marks.

Glycerin keeps skin hydrated throughout the day.

DERMATOLOGICALLY TESTED:

Effaclar has been through rigorous dermatological testing to ensure it is suitable for use on even the most sensitive skin. 9/10 dermatologists would recommend La Roche-Posay*.

MINIMALIST HYPO-ALLERGENIC FORMULA

The minimalist formula contains the best of our creations – designed for sensitive skin and all of its needs.Tested and re-tested for its efficacy and mildness on sensitive skin. It is also hypoallergenic.

INGREDIENTS

AQUA / WATER, GLYCERIN, DIMETHICONE, ISOCETYL STEARATE, NIACINAMIDE, ISOPROPYL LAUROYL SARCOSINATE, SILICA, AMMONIUM POLYACRYLOYLDIMETHYL TAURATE, METHYL METHACRYLATE CROSSPOLYMER, POTASSIUM CETYL PHOSPHATE, SORBITAN OLEATE, ZINC PCA, GLYCERYL STEARATESE, ISOHEXADECANE, SODIUM HYDROXIDE, MYRISTYLMYRISTATE, 2-OLEAMIDO-1, 3-OCTADECANEDIOL, ALUMINUM STARCH OCTENYLSUCCINATE, MANNOSE, POLOXAMER 338, DISODIUM EDTA, CAPRYLOYL SALICYLIC ACID, CAPRYLYL GLYCOL, VITREOSCILLA FERMENT, XANTHANGUM, POLYSORBATE 80, ACRYLAMIDE/SODIUM ACRYLOYLDIMETHYLTAURATE COPOLYMER, SALICYLIC ACID, PIROCTONE OLAMINE, PARFUM / FRAGRANCE. (CODE F.I.L.: B214027/1)